Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis

The early detection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important clinical need. In view of the suggested role played by bacterial translocation in liver disease and obesity, we sought to investigate the relationship between blood microbiota and liver...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 64; no. 6; pp. 2015 - 2027
Main Authors Lelouvier, Benjamin, Servant, Florence, Païssé, Sandrine, Brunet, Anne‐Claire, Benyahya, Salah, Serino, Matteo, Valle, Carine, Ortiz, Maria Rosa, Puig, Josep, Courtney, Michael, Federici, Massimo, Fernández‐Real, José‐Manuel, Burcelin, Rémy, Amar, Jacques
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.12.2016
Subjects
Online AccessGet full text
ISSN0270-9139
1527-3350
1527-3350
DOI10.1002/hep.28829

Cover

More Information
Summary:The early detection of liver fibrosis among patients with nonalcoholic fatty liver disease (NAFLD) is an important clinical need. In view of the suggested role played by bacterial translocation in liver disease and obesity, we sought to investigate the relationship between blood microbiota and liver fibrosis (LF) in European cohorts of patients with severe obesity. We carried out a cross‐sectional study of obese patients, well characterized with respect to the severity of the NAFLD, in the cohort FLORINASH. This cohort has been divided into a discovery cohort comprising 50 Spanish patients and then in a validation cohort of 71 Italian patients. Blood bacterial DNA was analyzed both quantitatively by 16S ribosomal DNA (rDNA) quantitative polymerase chain reaction and qualitatively by 16S rDNA targeted metagenomic sequencing and functional metagenome prediction. Spanish plasma bile acid contents were analyzed by liquid chromatography/mass spectrometry. The 16S rDNA concentration was significantly higher in patients of the discovery cohort with LF. By 16S sequencing, we found specific differences in the proportion of several bacterial taxa in both blood and feces that correlate with the presence of LF, thus defining a specific signature of the liver disease. Several secondary/primary bile acid ratios were also decreased with LF in the discovery cohort. We confirmed, in the validation cohort, the correlation between blood 16S rDNA concentration and LF, whereas we did not confirm the specific bacterial taxa signature, despite a similar trend in patients with more‐severe fibrosis. Conclusion: Changes in blood microbiota are associated with LF in obese patients. Blood microbiota analysis provides potential biomarkers for the detection of LF in this population. (Hepatology 2016;64:2015‐2027).
Bibliography:These authors contributed equally.
Potential conflict of interest: Dr. Amar consults for, received grants from, and owns stock in Vaiomer. Dr. Courtney is employed by and owns stock in Vaiomer. Dr. Burcelin consults for, received grants from, and owns stock in Vaiomer. Mr. Benyahya is employed by Vaiomer. Dr. Paisse is employed by Vaiomer. Dr. Lelouvier is employed by Vaiomer. Mrs. Valle is employed by Vaiomer. Mrs. Servant is employed by Vaiomer. Dr. Brunet is employed by Vaiomer.
The FLORINASH cohort is funded by the European Union as part of the 7th framework programme under grant agreement no. HEALTH‐F2‐2009‐241913. The metagenomic analysis was carried out with the financial support of DAEI (Direction de l'Action Économique et de l'Innovation) of the Midi‐Pyrénées Region, France. This study was supported by the Fondo Europeo de Desarrollo Regional (FEDER) and CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBERobn), an initiative of the Instituto de Salud Carlos III (ISCIII).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.28829